Intraperitoneal Erythropoietin

Treatment of Renal Anemia with Recombinant Human Erythropoietin

“…However, when r-huEPO was given in a CAPD-like regimen, absorption was less and correlated significantly with fluid absorption. In CAPD patients Frenken et al [105] observed a rise in hemoglobin values from 6.2 to 10.1 g/100 ml within 10 weeks of therapy, when r-huEPO was administered in a dose of 3 X 100 U/kg per week intraperitoneally. There from the authors concluded that the intraperitoneal route of administration represents an appropriate alter native in CAPD patients.…”

Controversies in Determination of Epoetin (Recombinant Human Erythropoietin) Dosages

“…In contrast, higher dosage (100 U/kg 3 times weekly) epoetin in a lL dialysate volume with a 10 to 12h dwell achieved therapeutic haematocrit levels (Frenken et al 1988). Even higher dosages of intraperitoneal epoetin (12000 Clin.…”

The Subcutaneous Administration Route of Epoetin: Advantages, Pain at the Injection Site and Patient Acceptance

“…The bioavailabillty of EPO administered intraperitoneally in dialysis fluid is about 3 to 8% (2). Although this would suggest that it is not an economical mode of treatment, an effective clinical response has been reported with l.p. EPO (3). Bioavailability is increased following injection into a dry peritoneal cavity (4).…”